GlassScriptPhysician profile
Kanaga N Sena
NPI 1730121377
$1,936.37
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $367.13 | 2019 | |
| Genzyme Corporation | $355.47 | 2019 | |
| Genentech USA, INC. | $248.98 | 2019 | |
| Biogen, INC. | $231.48 | 2019 | |
| Akcea Therapeutics, INC. | $159.56 | 2019 | |
| Amgen INC. | $125.00 | 2019 | |
| Emd Serono, INC. | $124.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.33 | 2019 | |
| Lilly USA, LLC | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.40 | 2019 | |
| Acorda Therapeutics, INC | $14.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanaga Sena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.